Millions of Americans now have access to an affordable alternative after Israel’s Teva Pharmaceuticals won approval to launch the first generic version of Novo Nordisk’s pricey Saxenda.
The injection could slash costs for patients paying over $1,300 a month, signaling a major shake-up for both insurers and competitors.
Read more: https://jewishbreakingnews.com/teva-wins-fda-approval-for-first-generic-weight-loss-drug/
No comments:
Post a Comment